Demographics and clinical history of IFN-I autoAbs-positive individuals
| . | Cohort . | Age (years) . | Sex . | HIV treatment status . | CD4+ count (cells/μl) . | IFN-I neutralized . | Collection year . | Infection history . | Prior IFN-α treatment . |
|---|---|---|---|---|---|---|---|---|---|
| P1 | Danish | 67 | Male | ART | 550 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2009 | • Rectal cancer (1992) • HCV co-infection • Streptococcus bovis bacteremia (2013) • Deceased: May 2020 • Cause of death: HCC | Yes |
| P2 | Danish | 29 | Female | ART | 310 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2011 | • Cervical HPV infection developing into LSIL (2012) and carcinoma in situ (2014) • Hospitalized with pneumococcal pneumonia (2016) | No |
| P3 | Danish | 52 | Female | ART | 830 | IFN-ω 200 pg/ml | 2019 | • HCV co-infection (chronic since 2002a) | Yes |
| P4 | American | 56 | Male | Naive | 741 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2009 | • Frequently hospitalized due to viremic episodes and community acquired pneumonia • History of HSV-2 infection (before 2009) • Episodes of disseminated VZV, RSV, parainfluenza, and mild COVID-19 infections (after 2009) | No |
| P5 | American | 28 | Male | Naive | 408 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2018 | • History of several episodes with STIs • Documented HSV-2 outbreak in 2018 • Diagnosed with MPox (after 2018) | No |
| . | Cohort . | Age (years) . | Sex . | HIV treatment status . | CD4+ count (cells/μl) . | IFN-I neutralized . | Collection year . | Infection history . | Prior IFN-α treatment . |
|---|---|---|---|---|---|---|---|---|---|
| P1 | Danish | 67 | Male | ART | 550 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2009 | • Rectal cancer (1992) • HCV co-infection • Streptococcus bovis bacteremia (2013) • Deceased: May 2020 • Cause of death: HCC | Yes |
| P2 | Danish | 29 | Female | ART | 310 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2011 | • Cervical HPV infection developing into LSIL (2012) and carcinoma in situ (2014) • Hospitalized with pneumococcal pneumonia (2016) | No |
| P3 | Danish | 52 | Female | ART | 830 | IFN-ω 200 pg/ml | 2019 | • HCV co-infection (chronic since 2002a) | Yes |
| P4 | American | 56 | Male | Naive | 741 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2009 | • Frequently hospitalized due to viremic episodes and community acquired pneumonia • History of HSV-2 infection (before 2009) • Episodes of disseminated VZV, RSV, parainfluenza, and mild COVID-19 infections (after 2009) | No |
| P5 | American | 28 | Male | Naive | 408 | IFN-ω 1 ng/ml IFN-ω 200 pg/ml | 2018 | • History of several episodes with STIs • Documented HSV-2 outbreak in 2018 • Diagnosed with MPox (after 2018) | No |
IFN, interferon; ART, antiretroviral therapy; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion; HSV-2, herpes simplex virus type 2; VZV, varicella-zoster virus; RSV, respiratory syncytial virus; STI, sexually transmitted infection
Chronic HSV infection cleared after IFN-α treatment.